Michael Ryskin
BofA Securities, Research Division

Thanks, everyone, for joining us. My name is Mike Ryskin. I'm on the BofA Life Science Tools and Diagnostics team. And for our next fireside chat, we're excited to host 10x Genomics. I'm excited to be hosted by Serge Saxonov, Chief Executive Officer; Adam Taich, Chief Financial Officer. Serge, Adam, thanks so much for being here.

Serge Saxonov
Co-Founder, CEO & Director

Thank you.

Adam Taich
CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer

Thank you for having us.

Michael Ryskin
BofA Securities, Research Division

Yes, format will be a fireside chat. If you've got a burning question, raise your hand, and we'll work it in. But other than that, let's kick things off. So Serge, Adam, you guys recently reported your first quarter, a lot of interesting updates for us. Maybe you could just give us a sort of high-level rundown of how the quarter played out, what you found most exciting, most interesting and just sort of how it flows through for the rest of the year?

Serge Saxonov
Co-Founder, CEO & Director

Yes, totally. So yes, really happy with the quarter, it was actually quite a strong performance along multiple dimensions in the quarter. So first of all, just like the fundamental mechanics of the business, the key drivers that we have been communicating for the past several quarters performed really well. So specifically, reaction growth in the single cell business once again showed double-digit growth.

And in fact, even like revenue